NASDAQ:BFRI
Biofrontera Inc.
Biofrontera Inc.'s revenue grew 11.7% in fiscal 2025 to $41.7M while operating margin rose to −27.2%, its highest in 6 years. Free cash flow was −$13.4M, −32.0% of revenue, and the diluted share count rose 84.4%.Summary generated from Biofrontera Inc.'s SEC filings. Latest annual report filed Mar 19, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$41.7M
Revenue growth+11.7%
Revenue, 5-yr CAGR+17.2%
Gross marginn/a
Operating margin−27.2%
Net margin−25.3%
ROICn/a
Return on equity−141.3%
Debt / equityn/a
Free cash flow−$13.4M
FCF margin−32.0%
Share count change+84.4%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 24 | 29 | 34 | 37 | 42 |
| Operating income | −25 | −19 | −23 | −17 | −11 |
| Net income | −38 | −1 | −20 | −18 | −11 |
| Free cash flow | n/a | −16 | −25 | −10 | −13 |
Recent filings
- 8-KOther events
Sep 14, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - 4Insider transaction report
Jul 29, 2026 - 4Insider transaction report
Jul 29, 2026 - 10-K/AAmended annual report for the fiscal year ended Dec 31, 2025
Jul 22, 2026 - 8-KResults of a shareholder vote
Jun 17, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 14, 2026